SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Angiology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Di Perri, T.
Right arrow Articles by Capecchi, P. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Di Perri, T.
Right arrow Articles by Capecchi, P. L.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Defibrotide Inhibits Ca2+ Dependent Neutrophil Activation: Implications for its Pharmacological Activity in Vascular Disorders

Tullio Di Perri

Institute of Clinical Medicine, Università di Siena, Policinico "Le Scotte," Siena, Italy

Franco Laghi Pasini

Institute of Clinical Medicine, Università di Siena, Policinico "Le Scotte," Siena, Italy

Linda Ceccatelli

Institute of Clinical Medicine, Università di Siena, Policinico "Le Scotte," Siena, Italy

Anna Laura Pasqui

Institute of Clinical Medicine, Università di Siena, Policinico "Le Scotte," Siena, Italy

Pier Leopoldo Capecchi

Institute of Clinical Medicine, Università di Siena, Policinico "Le Scotte," Siena, Italy

Defibrotide (DEF) is a polydeoxyribonucleotide agent provided with profibrinolytic and antithrombotic properties. Moreover, an antiischemic, cardi oprotective effect of the drug has recently been demonstrated in experimental animals. Increasing evidence exists of the important role played by neutrophils in the development of tissue damage during chronic and acute ischemia and in the early phases of reperfusion. In order to evaluate whether the overall cytoprotective effect of DEF could be based, at least in part, on a neutrophil- involving mechanism, the authors studied the in vitro effects of the drug on hu man neutrophil activation triggered by several specific stimuli.

The drug dose-dependently (10-100 µM) inhibited enzyme release, superoxide anion generation, and chemiluminescence induced in neutrophils by the chemoat tractant oligopeptide fMLP and by the divalent cation ionophores A23187 and ionomycin. The increase of extracellular calcium concentration from 0.5 to 2.0 mM antagonized the inhibitory effect of DEF. The use of the fluorescent probe Fura 2/AM led them to show that DEF is able to reduce the cytosolic free calci um increase following specific stimulation by affecting extracellular calcium en trance. Such a behavior resembles that of calcium-antagonistic drugs, thus suggesting that DEF works, at least in part, similarly to calcium entry blockers. Such an activity on cell calcium translocation could represent the underlying molecular mechanism of cytoprotection. Finally, the inhibitory action on neu trophil functions may play a role in tissue protection during ischemic injury.

Angiology, Vol. 42, No. 12, 971-978 (1991)
DOI: 10.1177/000331979104201206
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement